GeneDx HoldingsWGS
Recorded

GeneDx Holdings Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matt StantonAnalyst

We'll get started here. Matt Stanton on the life science tools diagnostics team. Happy to have GeneDx with us again at the conference this year. Kevin, appreciate you being here today.

Kevin FeeleyCFO

Great. Thanks for having us.

Matt StantonAnalyst

Maybe just to kick off, I think maybe just zoom out and we can kind of talk higher level, recap how the year's gone. I think there's been some fits and starts on the genome mix, some ASP, but fundamentally, you're on track to deliver volumes near 30% for the year again this year. Also targeting opportunities to expand sales force, working on RCM. Maybe just talk about kind of where things have gone according to plan, maybe things have exceeded, and where there's been a bit more of a challenge as we move through the year.

Kevin FeeleyCFO

Yeah. Thanks for having us. Always a highlight of the year. For those not familiar, GeneDx is a leader in providing genomics services to diagnose children with pediatric rare disease. In doing so, we're serving a large unmet clinical need out there. There's 30 million Americans alone with rare disease. That's one in 10. That's more than the cancer market. In the market strategy we have, it's to continue to move upstream in terms of getting physicians to order testing earlier on in order to end the diagnostic odyssey. In doing so, it means moving to new physician types, and we've embarked on a pretty ambitious plan to move beyond where these tests have resided in the past, which is within a small cohort of about 2,000 expert geneticists, and move into much larger physician and patient populations.

Kevin FeeleyCFO

The business, to your point, growing nicely, but throughout the year, a lot of lessons learned. I think what we owe investors, and ourselves frankly, is some more visibility into the business. There is a lot of known unknowns with respect to opening new markets. We have certainly seen some challenges, but when we step back, we have got a business that is growing volumes in the high 20s. It has got a gross margin profile solidified in the 30s. It is profitable. It has been a successful year. We have now seen sequential improvements in the overall business performance from Q1 to Q2 to Q3. Really proud of how the year has progressed, but it fell short of our initial expectations to start the year. Some volatility earlier in the year with respect to mix shift from exome as the leader within the portfolio into genome.

Kevin FeeleyCFO

That mix shift dynamic caught us a bit by surprise earlier in the year. It was catalyzed by strong demand out there by geneticists to move into a genome-only world and some competition. But at the end of it, what we have seen is physicians move from exome to genome, but not necessarily leave GeneDx. With that, saw a sharp rise earlier in the year into genome. That has put some pressure on some year-over-year comparisons. But when we take a step back, a move into genome is inherently a very good thing for our business and for the mission that we serve, which is to ultimately end the diagnostic odyssey. When I started at this company 11 years ago, the average age of diagnosis was about 14 years old. We now have it down to about five for children with rare disease.

Kevin FeeleyCFO

As we move into the much larger opportunity ahead, which is general pediatricians ordering exome or genome for children with global intellectual developmental delay, confident that through the course of the second half of this decade, we will continue to bring that number closer down to at or around birth.

Matt StantonAnalyst

Okay. Maybe on ASPs, up, I think, mid-single digits sequentially. It was about $100 better than expectations. Just talk about the upside ASP dynamics in 3Q. Was it some of the genome mix you talked about being lower? Was it better collections on those genomes? What drove the sequential ASP improvement? Then I guess, as it relates to 4Q, you are guiding for another sequential uptick of $100. Are those the same drivers? Are there different drivers? Is Carelon coming in more meaningfully? Just kind of unpack both the sequential improvement into 3Q and then what you are underwriting for 4Q here as well.

Kevin FeeleyCFO

Yeah. In Q3, both mix and underlying collection rate improvements contributed about equally. I think really pleased to see that the genome collection rate improved from 32% to 36% in the third quarter. What is most exciting about that is we are embarking on a multi-year revenue cycle transformation, one designed to capture more comprehensive, more accurate documentation further upstream in the order-to-result process in order to meet what is a wide array of disparate payer policies and specific documentation requirements. That work ongoing in implementation phase. The step up we have seen just this quarter alone without the much bigger opportunity to get far more payer-specific in terms of our workflows, attribute the improvement just this quarter to. In a word, slow down a bit to ensure that we are properly securing documentation and prior authorization before we begin sequencing of services.

Kevin FeeleyCFO

At this point, a bit of manual brute force to do that. There are some more sophisticated ways to ensure that process runs more efficiently in the future. In the third quarter, did put in some of that slowdown with respect to the genome product in order to try to secure higher reimbursement rates.

Matt StantonAnalyst

On 4Q, similar, is any of the Carelon dynamics starting to show up in 4Q, or is that more of a 2027 story?

Kevin FeeleyCFO

We began to see strong signals, early signals from payers that do look towards Carelon as lab benefit manager. I would not say the third quarter is fully baked in any of the benefit of that Carelon policy change. It will take several quarters really for it to have a building and stacking effect in the rates that we see. The fourth quarter does count on some incremental benefits in a continuation of that progress, but also continuation of the revenue cycle work to come, we think. In the fourth quarter, we do typically see a seasonal benefit that starts with a Q1 low point in terms of that average reimbursement rate and rises throughout the year.

Kevin FeeleyCFO

There's some seasonal uplift to come in the fourth quarter, continuation of the revenue cycle progress, and the majority of policy decisions such as Carelon and additional state Medicaid programs that have picked up policies in the past several quarters.

Matt StantonAnalyst

Okay. Maybe last one on ASP. You guys noted pretty significant improvement in the genome claims submitted to payers with active coverage. I think it was up 15% from, call it high 60s to low 80s. The percent of genome lives covered commercially today is 88%. Do we continue to march up towards 88 over time? Is there anything in terms of a lag effect between when that coverage flows through to the collection rates as well?

Kevin FeeleyCFO

Yes, would expect those rates to converge. Ultimately, a revenue cycle process aimed at making sure that we're matching, first and foremost, the test to the correct and appropriate individual clinical circumstance, but then also running tests that meet eligibility and policy criteria. Would expect over time the amount of claims submitted with payers with underlying policies to continue to converge, meaning rise in a bit of sequential fashion until those two numbers match each other. Look, the question of payer policies and covered lives turning into actual cash collections is at the heart of the work that we have to do. It's the most exciting opportunity financially for the business, but it also is one that fundamentally acknowledges that payer policy doesn't equal cash collection.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day